Heterozygous expression of the Alzheimer's disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses

Background A rare coding variant, P522R, in the phospholipase C gamma 2 (PLCG2) gene has been identified as protective against late-onset Alzheimer's disease (AD), but the mechanism is unknown. PLCG2 is exclusively expressed in microglia within the central nervous system, and altered microglial function has been implicated in the progression of AD. Methods Healthy control hiPSCs were CRISPR edited to generate cells heterozygous and homozygous for the PLCG2(P522R) variant. Microglia derived from these hiPSC's were used to investigate the impact of PLC gamma(P522R) on disease relevant processes, specifically microglial capacity to take up amyloid beta (A beta) and synapses. Targeted qPCR assessment was conducted to explore expression changes in core AD linked and microglial genes, and mitochondrial function was assessed using an Agilent Seahorse assay. Results Heterozygous expression of the P522R variant resulted in increased microglial clearance of A beta, while preserving synapses. This was associated with the upregulation of a number of genes, including the anti-inflammatory cytokine Il-10, and the synapse-linked CX3CR1, as well as alterations in mitochondrial function, and increased cellular motility. The protective capacity of PLC gamma 2(P522R) appeared crucially dependent on (gene) 'dose', as cells homozygous for the variant showed reduced synapse preservation, and a differential gene expression profile relative to heterozygous cells. Conclusion These findings suggest that PLC gamma 2(P522R) may result in increased surveillance by microglia, and prime them towards an anti-inflammatory state, with an increased capacity to respond to increasing energy demands, but highlights the delicate balance of this system, with increasing PLC gamma 2(P522R) 'dose' resulting in reduced beneficial impacts. [GRAPHICS] .

Automated summary

The rare coding variant PLC gamma 2 (P522R) has been found to protect against late-onset Alzheimer's disease by increasing microglial clearance of amyloid beta and preserving synapses. The variant also leads to alterations in gene expression and mitochondrial function. However, an increased dose of PLC gamma 2 (P522R) can result in reduced beneficial impacts.